Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accord Seeks To Capitalize On Portfolio And Partnerships

Company Points To Growth That Outperforms Peers

Executive Summary

Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.

You may also be interested in...



Who’s Hired? Accord’s Burt Moves On

Accord has announced the appointment of a replacement for James Burt, who has stepped down from his role as executive vice-president for the Europe, Middle East and North Africa region. Meanwhile, other organizations including NeuClone, the Medicines Patent Pool, KVK Tech and Strides have also announced executive appointments.

Accord Innovates With Cancer Support App

Accord Healthcare has launched an app to support cancer patients and help manage symptoms, incorporating expert data from Macmillan Cancer Support.

Accord Expands CNS Ambitions With Zubsolv Deal

Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel